Technology
OssioFixation – Transforming the orthopedic experience:
Promising improved clinical outcomes without changing orthopedic surgical technique

Ossio’s osteoconductive implant technology is based on a biocomposite material platform comprised of two primary components:

  1. Reinforcing synthetic bone fibers (continuous)
  2. Bioabsorbable polymer resin

The reinforcing mineral fibers are made of a mineral blend that has been clinically proven in several commercially available (FDA and CE Mark approved) synthetic bone filler products. The continuous fibers make up the majority of the implant and provide the superior mechanical properties, while the polymer resin binds the fibers together into a cohesive part.

Figure 1: Scanning electron microscopy (SEM) images of the reinforcing fibers distributed evenly between the polymer in an Ossio™ implant cross-section.

Degradation profile
The polymer degradation profile of the reinforced biocomposite is progressive and gradual. Thus, the biopolymer degradation products can be gradually cleared by the body. The accumulation of biopolymer degradation products, which has been seen with previous bioabsorbable implants, is avoided.

The mineral fiber content of the Ossio™ reinforced biocomposite is resorbed and replaced by bone. This process of biointegration is similar to the integration of synthetic bone filler products into the bone as the bone heals. The space that was occupied with bone filler becomes filled with healthy bone.

Figure 2: Histopathological images from an animal model, demonstrating new bone formation around and bone ingrowth into the territory of Ossio implants. This level of osteoconduction at 2 and 6 weeks is yet to be demonstrated in the world of biocomposites and bioresorbable materials.

 

Functionally, OssioFixation promises two key advantages:
-High initial and sustained mechanical strength, which provides excellent orthopedic fixation.
-Osteoconduction of the implant leading to complete bone in-growth, whereby the entire volume initially occupied by the Ossio implant is filled with healthy bone.

Healing and integration profile
As the operated bone or soft tissue regains strength during healing, the Ossio implant gradually loses its strength as both polymer and fibers degrade, but maintains its function through at least 12 weeks (normal bone healing is completed within 6-8 weeks).  Osteoconduction and bone integration take place within 12-18 months, leaving behind healthy bone and no residual hardware.

 

Current solutions
Traditional metal implants can provide sufficient mechanical strength for initial orthopedic fixation.  However, they can lead to a variety of post-operative complications and long-term negative sequelae: implant failure (related to the vastly different material properties vis-à-vis bone), infection, pain, and discomfort – all of which can require a subsequent surgical procedure to either remove or replace the hardware.

Beyond metal, there have been attempts to fabricate implants from various bioresorbable polymers, with or without a mineral component. These devices do not provide the required mechanical strength (they have a fraction of the strength of cortical bone) and most exhibit suboptimal degradation profiles that can result in burst release of acidic breakdown products and local inflammation. Complications that can be associated with these devices include local osteolysis, cyst formation, and implant failure.

 

OssioFixation is a breakthrough orthopedic fixation approach that builds upon existing orthopedic fixation techniques and reimbursement codes, and allows for osteoconduction and full bone in-growth.  OssioFixation thus promises to deliver superior clinical outcomes, reduce local complications and eliminate the need for unnecessary hardware removal procedures.

Strong Fixation
Promotes Bone Growth
Degrades Over Time
Same Surgical Technique
Existing Reimbursement
About Us

Ossio Ltd. is an orthopedic fixation company committed to transforming the orthopedic experience. The company is focused on developing and commercializing osteoconductive fixation implants, providing the first credible disruption to metal implants in the $6B+ orthopedic fixation implant market.

Founded in 2014, Ossio began as the culmination of years of biomechanical research and a vision for the possibility of healing bone better. The technological basis of osteoconductive fixation was developed and would lay the groundwork for ushering in a new era of OssioFixation™ – orthopedic fixation with hardware that can be fully replaced by bone in a progressive process of bone in-growth into the implant.

Ossio strives to transform the orthopedic experience by encouraging natural bone healing that will ultimately eliminate hardware removal procedures, minimize implant-related complications, minimize pain, and dramatically improve the health economics of orthopedic fixation.

Ossio has its development headquarters in Binyamina, Israel and its commercial headquarters in Boston, Massachusetts.

The Ossio Team
Meet our highly experienced team members
Brian Verrier
Brian Verrier
Chief Executive Officer

Mr. Verrier was Vice President & General Manager of Vascular Therapies at Covidien, where he grew the Peripheral Vascular Business from $700M to more than $1.2B. Before that he was Vice President of US Sales for Medtronic Vascular.

Orahn Preiss-Bloom
Orahn Preiss-Bloom
Founder & President, Strategic Innovation

Founder and COO/CTO of LifeBond, where developed two biosurgical product families to commercial stage and raised $60M, including from Johnson & Johnson Development Corporation. Biomechanics researcher at IDF Institute for Military Physiology and at Columbia University NY, Dept. of Orthopedic Surgery. M.Sc. in biomedical engineering from the Technion, Israel Institute of Technology.

Brennan Marilla
Brennan Marilla
Chief Commercial Officer

Brennan has a successful, 25 year track record of driving growth and commercializing transformative therapies in med-tech. He most recently served as Chief Commercial Officer for Surgical Specialties Corp, where significant improvements in top and bottom line performance led to acquisition by Vivo Capital in 2017. Prior, he was VP & GM of Covidien’s $650M Endovascular business and VP, Sales and Marketing for their $1B+ Peripheral Vascular sector. In his tenure, these franchises rapidly transformed into a market leading brand through multiple product introductions, disruptive technology acquisitions, and market development campaigns.   Before Covidien, he spent 12 years at Medtronic where he was VP, US Sales and Director, Global Marketing for their aortic stent graft business, where he helped develop these therapies into what is now the standard of care in a $2 billion global market.

Moshe Shneor
Moshe Shneor
CPA, MBA, Chief Financial Officer

Previously, Chief Executive at Pollogen (acquired by Lumenis) following service as Chief Financial & Operations Officer.  Beforehand, Senior Manager at Ernst & Young, where focused on international hi-tech Nasdaq-traded corporations. MBA from Tel Aviv University.

Taly Lindner
Taly Lindner
PhD, Vice President of Scientific & Regulatory Affairs

Dr. Lindner joined Ossio after returning to Israel from the US, where she completed a post-doctoral fellowship at the California Institute of Technology (CalTech) in bio-inspired design. Previously, Taly worked as a Senior Engineer at Theracell, a biomedical start-up in California. Taly holds a Ph.D. and a B.Sc. in biomedical engineering from the Technion, Israel Institute of Technology, where she specialized in the biomechanics of biomaterials.

Ilan Uchitel
Ilan Uchitel
Vice President of Research & Development

Mr. Uchitel has more than 15 years of R&D experience in the medical device and defense industries. Previously, he served as VP R&D in various medical device companies in the fields of electrophysiology, invasive cardiology, and minimally invasive implantable maxillofacial solutions. Prior to that, Ilan held numerous R&D and project management positions at an elite technology unit of the Israeli Intelligence Corps. Ilan earned a B.Sc. in mechanical engineering, an M.Sc. in biomedical engineering and an MBA – all from Tel-Aviv University.

Ronit Merchav-Feuermann
Ronit Merchav-Feuermann
DVM, Medical Director

Dr. Merchav-Feuermann is a veterinary surgeon with advanced surgical training. She amassed 15 years of experience in veterinary orthopedics in both the academic environment in Israel, and in the private sector in the United States. Ronit is a leader in the Medical Department of Ossio and manages its extensive cutting-edge preclinical program. Ronit holds a DVM from the Hebrew University of Jerusalem.

Amir Peled
Amir Peled
Director of Products

Mr. Peled served as a Product Line and Program Manager at Syneron Medical (NASDAQ:ELOS), which was acquired by Apax Partners for $397M. Prior to that, established the biomaterials business at Alpha-Bio Tec., a subsidiary of Nobel Biocare (OTCMKTS:NBHGF), which was acquired by Danaher (NYSE:DHR) for $2.2B. Earlier, Amir lead the entry into 10 different care areas at Q Core Medical, internationally distributed by Hospira, part of Pfizer (NYSE:PFE). Amir holds a B.Sc. in mechanical engineering and an M.Sc. in biomedical engineering, both from the Ben-Gurion University of the Negev.

Udi Wexler
Udi Wexler
Senior Engineering Manager

Mr. Wexler managed the production line engineering at Medtronic (formerly Covidien and Given Imagining) for 10 years, building, releasing, and sustaining the entire production lines of the company. Prior to that, Udi was a Project Manager at Remon Medical, which was acquired by Boston Scientific (NYSE:BSX) for $300M, and a Designer and Project Manager at Aran R&D (TLV:ARAN). He holds an MBA from the NYU Polytechnic School of Engineering, and a B.Sc. in mechanical engineering from the Technion, Israel Institute of Technology.

Kety Bardugo
Kety Bardugo
Senior Quality Assurance Manager

Ms. Bardugo has more than 15 years of experience in Quality Assurance in the medical device industry. She served as a QA Manager at EndoChoice (NYSE:GI), which was acquired by Boston Scientific (NYSE:BSX) for $210M. Prior to that, she successfully established a quality management system for an FDA premarket approval audit at Dune Medical Devices Ltd. Key holds a B.A. in Business Administration from the University of Haifa and a quality engineering degree from Afikei Yeda College.

Board of Directors
Mr. Udi Gilboa
Mr. Udi Gilboa
Executive Chairman

Founder and managing partner of Top Notch Capital, a prominent Israeli life sciences investment bank. Co-founder, Director and former CFO of BioBlast Ltd (NASDAQ: ORPN). Co-founder, Director and former CFO at Alcobra Ltd (NASDAQ: ADHD). Director at Insuline Medical Ltd.

Mr. Joseph Darling
Mr. Joseph Darling

Mr. Darling served as COO at Interventional Spine, Inc.  Before that, as President of Linvatec Corporation and Executive Vice President, Commercial Operations at CONMED Corporation. Mr. Darling also served as a Senior Vice President & General Manager of the Biologics and Sports Medicine Business Unit at Smith & Nephew Inc.

Mr. Ken Reali
Mr. Ken Reali

Mr. Reali is the President & CEO of Clinical Innovations, LLC, a woman’s healthcare company. Previously, he was the President & CEO of Baxano Surgical, a spinal implant company.  Mr. Reali also has served as a Senior VP and General Manager of the Biologics and Spine group at Smith & Nephew.

Sanket S. Parekh
Sanket S. Parekh

Sanket S. Parekh is the President of Pidilite USA, Inc. the US subsidiary of Pidilite Industries, a multinational publicly traded consumer products company that was started by his family in the 1950’s. In addition, Sanket is the Managing Partner of Secocha Ventures, a private fund focused on early stage companies in technology, consumer products & services and healthcare technology.

Shmulik Zysman
Shmulik Zysman
Attorney at Law

Founder of ZAG-S&W – an international law firm providing global law solutions. Shmulik is one of Israel’s foremost commercial lawyers with over 30 years of experience in the fields of life sciences, hi-tech, internet, commercial and capital markets law. Mr. Zysman represents companies in all stages: from pre-seed stages through their growth, as well as with IPO`s and mergers or acquisition.

Mr. Zysman is one of Israel’s Hall of Fame basketball players. He was a prominent player in the Israeli Premier league for 17 years, and played on the Israeli National Team.

Dr. Kerry Assil
Dr. Kerry Assil
MD

Dr. Kerry Assil is a world renowned Ophthalmologist and serial entrepreneur who has developed and pioneered numerous advances in the field of eye surgery and served on the boards of numerous national and multinational companies. He has also been the founder or co-founder of many companies, all sharing the common theme of imparting positive social impact. These companies have included;

  • 9021 SMC – Founded Multispecialty Ambulatory Surgical Center in 2006, with majority stake sold to Cedars Sinai Health System in 2016 (investors achieving a greater than 10x average return).
  • Agro Vision Corp. – Co-Founded in 2011. Mega Farming project and food company with its major land holding in northern coastal Peru (original investors have experienced a 25x increase in their individual asset value).
  • Aris Vision – Founded Network of 40 lasik centers – founded in 1996.
  • The Assil Eye Institute – Founded in 1995.
Contact Us
Have any questions or ideas? Feel free to contact us!
Address

58 HaTachana Street, Binyamina, Israel.

Boston, USA.

We are hiring!

Join us in creating a new reality in orthopedics

Ossio is a young, fast growing company that is always on the lookout for talented people to join its multidisciplinary team. If you are highly motivated and inspired to heal bone better, please send your CV to info@ossio.io.